Estados Unidos - inglés - NLM (National Library of Medicine)

american health packaging - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease control (cdc) and american thoracic society for complete regimen and dosage recommendations. 4 pyrazinamide is contraindicated in persons: - with severe hepatic damage. - who have shown hypersensitivity to it. - with acute gout.

Malta - inglés - Malta Medicines Authority

morningside healthcare limited unit c, harcourt way, leicester, le19 1wp, united kingdom - pyrazinamide - tablet - pyrazinamide 500 mg - antimycobacterials

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sandoz - pyrazinamide - tablet - 500 mg

Kenia - inglés - Pharmacy and Poisons Board

pyrazinamide - tablet - 150mg - pyrazinamide

Estados Unidos - inglés - NLM (National Library of Medicine)

ax pharmaceutical corp - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 24.75 kg in 25 kg

Filipinas - inglés - FDA (Food And Drug Administration)

n/a; importer: 2 world traders subic inc.; distributor: 2 world traders subic inc. - zinaf-500 - tablet - 500mg

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - myambutol is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: myambutol plus isoniazid myambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, myambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used with myambutol have incl

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - myambutol is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: myambutol plus isoniazid myambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, myambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used with myambutol have incl

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with e

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used